Servier Reports P-III Trial (INDIGO) Results of Vorasidenib for IDH-Mutant Low-Grade Glioma
- The P-III trial (INDIGO) evaluating vorasidenib monotx. vs PBO in 340 patients with residual or recurrent IDH mutant low-grade glioma. Enrolled patients had residual or recurrent grade 2 oligodendroglioma or astrocytoma with an IDH1 or IDH2 mutation and had undergone surgery
- The trial met its 1EPs & 2EPs i.e., the therapy showed an improvement in PFS & time to next intervention (TTNI) & results of the prespecified interim analysis were significant and clinically meaningful
- Additionally, the safety profile was consistent with prior published data & results will be presented at an upcoming medical meeting
Ref: PRNewswire | Image: Servier
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.